Business Wire

Prometheus Materials’ Bio-Cement and Bio-Concrete Achieves 12x the Sound Absorption of Traditional Concrete in ASTM Testing

2.8.2023 15:00:00 EEST | Business Wire | Press release

Share

Prometheus Materials, a leader in sustainable building materials, announced today the achievement of remarkable results in the ASTM C423 sound-absorption testing of its ground-breaking bio-cement and bio-concrete technology. The company develops revolutionary zero-carbon building solutions that provide a superior alternative to carbon-intensive portland cement.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230802310284/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Prometheus Materials' superior sound-absorption performance compared to traditional concrete (Graphic: Business Wire)

The Johns Manville Technical Center in Littleton, Colorado – a world-class research and development facility – conducted the independent testing, which found that Prometheus Materials’ bio-concrete demonstrated a Noise Reduction Coefficient (NRC) of 0.60. This NRC rating indicates 60% sound absorption – twelve times that of traditional concrete.

Prometheus Materials’ initial pre-cast bio-concrete product line includes masonry units, segmented modular block and acoustic panels – where this exceptional sound-absorption characteristic will be an essential feature – as well as paving stones and grass pavers. These products are currently available strictly for select projects, with commercial availability slated for the first half of 2024.

Such unrivaled sound absorption is a cost-saving, environment-enhancing boon for various sectors. In settings where noise can be damaging or distracting, builders are often forced to rely on secondary products to achieve some measure of noise reduction. Beyond the added expense, these materials can sometimes have negative effects – including health risks. However, with Prometheus Materials’ bio-cement and bio-concrete products, such facilities can incorporate sound-absorption capabilities without additional cost, safety concerns or other drawbacks. Residential, commercial and institutional buildings, amphitheaters, music studios, highway barriers – and a vast array of other end-uses – will all benefit from this exceptional noise-reduction capability, while concurrently reducing their carbon footprint.

“Our latest ASTM testing results embody our commitment to innovative design,” said Loren Burnett, President, CEO & Co-founder of Prometheus Materials. “We’ve developed a novel material that provides a zero-carbon alternative to traditional concrete while delivering additional performance benefits and applications. We’re proud to pave the way toward a more technologically advanced and environmentally responsible future for the construction industry.”

Vishaan Chakrabarti, FAIA FRAIC – renowned architect, academic and business leader with focus on sustainable design; Founder and Creative Director of Practice for Architecture & Urbanism (PAU); and member of Prometheus Materials’ Board of Directors – was equally inspired. “Test results like these prove that Prometheus Materials has developed far more than zero-carbon concrete – which by itself is an enormous accomplishment,” he said. “With this level of sound absorption, as well as other characteristics currently being tested, it's clear that this material will offer a suite of products based on entirely redefined ideas of what concrete can be and do.”

Prometheus Materials continues to lead the charge in sustainability and innovation within the building materials sector. With these ASTM C423 sound-absorption results joining its previously secured ASTM C129 and C90 certifications – plus other features of its bio-cement and bio-concrete that are comparable or superior to traditional concrete – the company is poised to drive the construction industry toward a more cutting-edge and sustainable future.

About Prometheus Materials

Prometheus Materials provides sustainable building materials that accelerate the world’s transition to a carbon-negative future. Inspired by biological processes found in nature, the company’s process uses microalgae to produce a bio-cement that offers an alternative to carbon-intensive portland cement. When mixed with aggregate, this bio-cement forms a zero-carbon bio-concrete with mechanical, physical and thermal properties that rival those of portland cement-based concrete. Learn more about how the company enables the decarbonization of the construction industry at prometheusmaterials.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Liz Crumpacker
Antenna Group
prometheus@antennagroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 15:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. The oral presentation of these data is taking place at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2, 2026, in Chicago (Abstract #LBA7000. Session: Oral Abstract Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia. May 30, 4:00 – 7:00 p.m. ET [3:00 – 6:00 p.m.

Fortegra Completes Acquisition by DB Insurance29.5.2026 23:30:00 EEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 23:01:00 EEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye